Can Foundayo and Ubrelvy Be Taken Together?
Yes, Foundayo (orforglipron) and Ubrelvy (ubrogepant) can be safely co-administered without contraindications or clinically significant drug interactions.
No Known Drug Interactions
There are no documented pharmacokinetic or pharmacodynamic interactions between orforglipron (a GLP-1 receptor agonist) and ubrogepant (a CGRP receptor antagonist). These medications work through completely different mechanisms:
- Foundayo (orforglipron): Oral GLP-1 receptor agonist for weight management and type 2 diabetes 1
- Ubrelvy (ubrogepant): Oral CGRP receptor antagonist for acute migraine treatment 2
Supporting Evidence
The 2025 BMJ diabetes guideline explicitly addresses combination therapy for GLP-1 receptor agonists, stating that "most medications for which recommendations are provided can be used in combination" with specific exceptions noted only for combining GLP-1 receptor agonists with tirzepatide (which share similar mechanisms) 3. No restrictions are mentioned for combining GLP-1 agonists with migraine medications.
Additionally, research on CGRP antagonists demonstrates their safety when combined with other medication classes. Studies evaluating ubrogepant with atogepant (another CGRP antagonist) showed no clinically meaningful pharmacokinetic interactions 4, 5, and real-world data confirms ubrogepant's safety when combined with anti-CGRP monoclonal antibodies 6.
Clinical Considerations
Gastrointestinal Side Effects
Both medications can cause GI adverse events:
- Foundayo: Nausea (26-35%), vomiting (13-24%), diarrhea (21-25%), constipation (20-27%) 1
- Ubrelvy: Generally well-tolerated with minimal GI effects 2
Monitor for cumulative GI symptoms, particularly during Foundayo dose escalation when GI effects are most prominent. The 2025 BMJ guideline notes that patients already taking medications with GI side effects may choose to avoid adding drugs with similar profiles if cumulative risk exceeds anticipated benefits 3.
Practical Management
- Start Foundayo with gradual dose escalation to minimize GI effects 1
- Use Ubrelvy as needed for acute migraine attacks (no daily dosing restrictions)
- GI side effects from Foundayo typically decrease over time and are highest during dose escalation 1
- Consider timing Ubrelvy doses away from peak Foundayo GI symptoms if needed
Important Foundayo Warnings
Be aware of Foundayo-specific precautions that are unrelated to Ubrelvy co-administration:
- Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN 2 1
- May reduce efficacy of oral hormonal contraceptives (switch to non-oral method or add barrier method for 30 days after initiation and each dose escalation) 1
- Delays gastric emptying; inform providers before surgeries requiring anesthesia 1
Bottom Line
There is no medical reason to avoid combining Foundayo and Ubrelvy. The medications target different therapeutic areas through distinct mechanisms, with no documented interactions. Standard monitoring for individual medication side effects applies, with particular attention to cumulative GI symptoms during Foundayo initiation.